VRCA stock forecast
Our latest prediction for Verrica Pharmaceuticals, Inc.'s stock price was made on the Oct. 10, 2019 when the stock price was at 15.08$.
In the short term (2weeks), VRCA's stock price should outperform the market by 5.70%. During that period the price should oscillate between -8.72% and +14.25%.
In the medium term (3months), VRCA's stock price should outperform the market by 3.17%. During that period the price should oscillate between -19.62% and +33.77%.Get email alerts
About Verrica Pharmaceuticals, Inc.
Verrica Pharmaceuticals, Inc. operates as a clinical-stage medical dermatology company, which engages in identifying, developing, and commercializing pharmaceutical products for the treatment of skin diseases. Its lead product VP-102, is a proprietary topical therapy used in common skin indications including Molluscum contagiosum and Verruca Vulgaris. The company was founded by Matthew Davidson on July 3, 2013 and is headquartered in West Chester, PA.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of -0.33$ per share.
The book value per share is 3.95$
Three months stock forecastOct. 10, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|